Saad O. Atiq

Oncology
1 Gustave L Levy Pl
New York, NY 10029

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

External control arms can validate treatment efficacy in single-arm studies.

External control arms can validate treatment efficacy in single-arm studies.

Journal: Journal of the National Cancer Institute
Published: March 24, 2026

A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

Journal: Cancer discovery
Published: October 09, 2025

A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationale.

A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationale.

Journal: Future oncology (London, England)
Published: June 23, 2025

The Evolving Treatment Paradigm for Upper Tract Urothelial Carcinoma.

The Evolving Treatment Paradigm for Upper Tract Urothelial Carcinoma.

Journal: European urology focus
Published: June 04, 2025

E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale.

E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale.

Journal: Future oncology (London, England)
Published: May 27, 2025

A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationale.

A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationale.

Journal: Future oncology (London, England)
Published: March 21, 2025

Antibody-drug conjugates in rare genitourinary tumors: review and perspectives.

Antibody-drug conjugates in rare genitourinary tumors: review and perspectives.

Journal: Current opinion in oncology
Published: March 20, 2025

Top advances of the year: Bladder cancer.

Top advances of the year: Bladder cancer.

Journal: Cancer
Published: February 10, 2025

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis.

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis.

Journal: BMJ oncology
Published: August 01, 2024

New Therapeutic Horizons for Advanced or Metastatic Penile Cancer.

New Therapeutic Horizons for Advanced or Metastatic Penile Cancer.

Journal: The Urologic clinics of North America
Published: June 26, 2024

The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.

The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.

Journal: Urologic oncology
Published: May 12, 2021

A Case of Metastatic Pancreatic Adenocarcinoma in Complete Remission Using Chemotherapy and Immunotherapy.

A Case of Metastatic Pancreatic Adenocarcinoma in Complete Remission Using Chemotherapy and Immunotherapy.

Journal: Cureus
Published: March 17, 2021
Showing 1-12 of 16

Last Updated: 09/26/2026